Search results for "Remdesivir"

showing 3 items of 3 documents

Transient asymptomatic bradycardia and Remdesivir in COVID-19 patients

2022

BACKGROUND: COVID-19 is an infectious disease caused by a coronavirus in humans, namely SARS-CoV-2, which has quickly become a global pandemic. The infection is responsible for a severe form of pneumonia, which may lead to lung failure and death. Among the therapeutic strategies, the antiviral agent Remdesivir has become one of the most used drugs. The current literature reports a causal correlation between Remdesivir administration and the incidence of cardiovascular effects. We aimed at further investigating this relationship, by exploring the association between the use of Remdesivir and the onset of bradyarrhythmic disorders. METHODS: We reviewed medical records, blood exams and chest i…

BradycardiaRemdesivirCOVID-19General Medicine
researchProduct

Length of remdesivir treatment in patients with severe COVID-19

2021

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has caused more than 96 million cases and over 2 million deaths worldwide as of January 21, 2021. As the crisis continues, the scientific community, institutions and pharmaceutical industries are striving to find effective therapies to prevent or treat the disease. Remdesivir (GS-5734) was early identified as an option.

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)RC705-779Journal Clubbusiness.industry4Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RemdesivirMEDLINEExpert Opinion03 medical and health sciencesRegimenDiseases of the respiratory system0302 clinical medicine030228 respiratory systemSAFERMedicineIn patient030212 general & internal medicinebusinessBit (key)Breathe
researchProduct

The profile of hospitalized Covid-19 patients and evaluation of Remdesivir effectiveness

2022

Remdesivir ir viens no potenciāli klīniski efektīviem medikamentiem COVID-19 infekcijas ārstēšanā, samazinot hospitalizācijas ilgumu un mortalitāti. Darba mērķis: Izvērtēt hospitalizēto pacientu profilu un remdesivir klīnisko efektivitāti. Materiāli un metodes: Retrospektīvais pētījums tika veikts Latvijas Infektoloģijas centra arhīvā. Tika analizēti 180 pacienti, kas dalījās divās grupās. Kontroles grupā bija 35 pacienti un tie nesaņēma remdesivir terapiju. Remdesivir grupas 145 pacienti saņēma šo medikamentu terapijā. Tika analizēti demogrāfiskie, epidemioloģiskie, laboratorie un klīniskie rādītāji, kā arī medikamenta efektivitāte. Nozīmīgākie rezultāti: Vidējais vecums remdesivir grupai …

SARS-CoV-2RemdesivirCOVID-19COVID-19 ārstēšanaMedicīna
researchProduct